Delivery Order SPE2DB25D2204-SPE2DB25FTGVZ
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 26, 2025, for the supply of Jatenzo 237 mg capsules (120 count) valued at $1,640.34. This firm fixed-price delivery order, which is scheduled for completion by August 27, 2025, represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical. The award was made through open competition with no set-aside designation. AmerisourceBergen,...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 12, 2025, for the supply of Jatenzo 198 mg capsules (120-count units) valued at $1,131.88 under a firm fixed-price contract. This is a non-set-aside competitive award with an ultimate completion date of August 13, 2025, and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 17, 2025, for the supply of Jatenzo 237 mg capsules (120 count) with a ceiling value of $2,263.74. This is a firm fixed-price contract with an ultimate completion date of September 18, 2025. The award was competitively made with no set-aside designation, and performance will take place at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. As a child delivery order under a...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Jatenzo 158 mg capsules (120-count unit) under a firm fixed-price contract with a ceiling value of $1,983.45. The award, made on September 8, 2025, is a non-set-aside competitive award with an ultimate completion date of September 9, 2025. This delivery order is executed against AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, a $999.999 billion...
- The Defense Logistics Agency awarded a delivery order valued at $1,131.87 to AmerisourceBergen Drug Corp on August 7, 2025, for the supply of Jatenzo 237 mg capsules (120-count units). This is a firm fixed-price, non-set-aside contract with a completion date of August 8, 2025, and will be performed at the contractor's corporate office in Conshohocken, Pennsylvania. Jatenzo is a testosterone replacement therapy indicated for hypogonadism treatment, reflecting the federal government's...
- The Defense Logistics Agency awarded a delivery order valued at $2,263.74 to AmerisourceBergen Drug Corp for 120 capsules of Jatenzo 237 mg on July 29, 2025, with an ultimate completion date of July 30, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. Jatenzo is a testosterone replacement therapy medication used to treat hypogonadism in adult males,...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 18, 2025, for the supply of Jatenzo 237 mg capsules (120 count) at a ceiling value of $2,263.74. This contract represents a firm fixed-price delivery order with no set-aside designation, indicating competitive award to the vendor. The ultimate completion date is set for August 19, 2025, with performance originating from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Jatenzo 237 mg capsules (120 count) under a firm fixed-price contract with a ceiling value of $1,131.87. The contract, awarded on July 31, 2025, with an ultimate completion date of August 1, 2025, represents a non-set-aside competitive award. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, will perform the work at its Corporate Office location. This delivery...
- The Defense Logistics Agency awarded a delivery order valued at $1,256.92 to AmerisourceBergen Drug Corp for 120 capsules of Jatenzo 158 mg on July 14, 2025, with completion scheduled for July 15, 2025. This firm fixed-price, competitively awarded contract represents a small-value pharmaceutical delivery with no set-aside designation. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under the company's larger...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on May 12, 2025, for the supply of Jatenzo 237 mg capsules (120-count units) with a ceiling value of $1,131.87. The contract is classified as a firm fixed price delivery order with an ultimate completion date of May 13, 2025, and represents a competitively awarded, non-set-aside procurement. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office...
- SPE2DB25D2204Indefinite Delivery Contract
- SPE2DB25D2204-SPE2DB25FTGVZDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 8, 2025, for the supply of Jatenzo 237 mg capsules (120-count units) with a ceiling value of $2,263.74. This is a firm fixed price delivery order with an ultimate completion date of August 11, 2025, and carries no set-aside designation, indicating it was competitively awarded. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor and critical vendor for federal medical procurement, particularly supporting military and veteran healthcare systems. This delivery order operates under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The IDC serves as a comprehensive global pharmaceutical support vehicle enabling the company to supply a wide range of pharmaceutical products and medical supplies to support military healthcare programs worldwide. Jatenzo, a testosterone replacement therapy, represents one of the specialized pharmaceutical products delivered through this contract vehicle to support Defense Health Agency and other federal healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $2.3k | 8/8/25 |